NRIX

Nurix Therapeutics reported Q3 2026 earnings of $4.73 per share, significantly beating the consensus estimate of a loss of $0.56 per share, with a 944.64% earnings surprise. Revenues reached $673.06 million, surpassing estimates by 383.11%. However, the stock received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions and the company's industry ranking in the bottom 33% of sectors.

Swiss pharma giant Roche Holding AG reported first-nine-month 2026 sales of CHF 46.5 billion, up 6% at constant exchange rates, driven by 7% growth in its Pharmaceuticals division. Five key drugs generated CHF 16.8 billion in sales, up 12% at CER, offsetting declines in legacy products due to loss of exclusivity.

The company reaffirmed mid-single-digit sales growth guidance for 2026 and expects high-single-digit EPS growth. Roche's pipeline includes promising candidates in oncology, immunology, and obesity treatment, with enicepatide showing encouraging phase II results for type 2 diabetes and weight management.

Kymera Therapeutics is developing KT-621, an oral STAT6 degrader in phase IIb trials for atopic dermatitis and eosinophilic asthma. The company completed enrollment in the BROADEN2 study ahead of schedule with top-line data expected by end of 2026.

Future growth depends on trial outcomes, regulatory approval, and successful commercialization. The company faces competition from Arvinas and Nurix in the protein degradation therapy space.

Economic data shows mixed signals with softer-than-expected PCE inflation and stronger-than-expected Q2 GDP growth. Market attention is turning to Friday's employment report. Precigen shares surged 6.3% on growing investor confidence in sales of its FDA-approved drug Papzimeos for recurrent respiratory papillomatosis, with expected quarterly earnings up 181.8% year-over-year.